

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WAI YUEN TONG MEDICINE HOLDINGS LIMITED

(位元堂藥業控股有限公司*)

(Incorporated in Bermuda with limited liability)

(Stock Code: 897)

INSIDE INFORMATION EXPECTED IMPROVEMENT IN RESULTS

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and Inside Information Provisions under Part XIVA of the SFO.

The Board wishes to inform the shareholders and potential investors of the Company that based on the preliminary review of the draft unaudited consolidated management accounts of the Group and the information currently available to the Board, the Group is expected to record a substantial decrease in consolidated net loss attributable to owners of the parent or even a profit for the year ended 31 March 2019 as compared to the loss for the year ended 31 March 2018, notwithstanding there is a decrease in gross profit due to a decrease in turnover for the year ended 31 March 2019 when compared to the corresponding period in 2018.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by Wai Yuen Tong Medicine Holdings Limited (位元堂藥業控股有限公司*) (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

The board of directors (the “**Board**” or the “**Directors**”) of the Company wishes to inform the shareholders and potential investors of the Company that based on the preliminary review of the draft unaudited consolidated management accounts of the Group and the information currently available to the Board, the Group is expected to record a substantial decrease in consolidated net loss attributable to owners of the parent or even a profit for the year ended 31 March 2019 as compared to the loss for the year ended 31 March 2018, notwithstanding there is a decrease in gross profit due to a decrease in turnover for the year ended 31 March 2019 when compared to the corresponding period in 2018. Such expected improvement was mainly attributable to, among of other things, (i) a gain on bargain purchase of additional equity interests in an associate; and (ii) an improvement in results of such associate. The final results are subject to the finalisation of various valuation required under Hong Kong Financial Reporting standards, which are being prepared by the valuers of the Company and to be agreed by the independent auditors of the Company. As such, the Company cannot determine the exact improvement in its results until such valuations are finalised.

*For identification purpose only

As the Company is still in the course of finalising its annual results for the year ended 31 March 2019, the information contained in this announcement is only based on the preliminary review of the draft unaudited consolidated management accounts of the Group for the year ended 31 March 2019 and the information currently available to the Board which have yet to be confirmed, reviewed or audited by the independent auditors of the Company. Details of the performance of the Group for the year ended 31 March 2019 will be disclosed in the annual results announcement of the Company which is expected to be published on or before end of June 2019 in accordance with the requirements under the Listing Rules.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
WAI YUEN TONG MEDICINE HOLDINGS LIMITED
(位元堂藥業控股有限公司*)
Chan Chun Hong, Thomas
Executive Director

Hong Kong, 12 June 2019

As at the date of this announcement, the executive Directors are Mr. Tang Ching Ho, Mr. Chan Chun Hong, Thomas, Ms. Tang Mui Fun and Ms. Tang Wai Man and the independent non-executive Directors are Mr. Siu Man Ho, Simon, Mr. Leung Wai Ho, Mr. Cho Wing Mou and Mr. Li Ka Fai, David.

* For identification purpose only